Dova Pharmaceuticals Inc. DOVA Income Statement

Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16
Revenue
Revenue
13,732	13,288	14,356	10,355	0	0	0	-	-	-	-	-	-	-
Operating expenses:
Cost of product sales
1,903	1,620	1,695	1,180	0	0	0	-	-	-	-	-	-	-
Research and development
18,310	18,969	18,972	18,304	15,485	16,064	14,849	15,709	19,939	21,271	24,968	0	0	0
Selling, general and administrative
-	-	-	61,921	-	-	-	13,499	0	0	0	-	-	-
Selling, general and administrative
0	0	0	-	0	0	0	-	-	-	-	0	0	0
Total operating expenses
86,724	84,934	88,081	81,405	68,685	56,048	37,654	29,208	27,542	25,057	27,112	0	0	0
Loss from operations
-72,992	-71,646	-73,725	-71,050	-61,172	-51,464	-37,654	-29,208	-27,542	-25,057	-27,112	0	0	0
Interest income and other income (expense), net
1,486	1,593	959	644	612	494	675	486	261	27	0	0	0	-
Interest expense - related party
-	-	-	-	-	-	-	-	-	-	-	0	0	0
Interest expense
2,554	2,245	2,125	1,876	1,690	1,480	1,321	1,232	972	671	0	0	0	-
Total other expenses, net
-1,068	-652	-1,166	-1,232	-1,078	-986	-646	-746	-712	-648	-340	0	0	0
Interest income and other income (expense), net
1,486	1,593	959	644	612	494	675	486	0	0	0	-	-	-
Net loss
-74,060	-72,298	-74,891	-72,282	-62,250	-52,450	-38,300	-29,954	-28,254	-25,705	-27,452	0	0	0
Net loss per share, basic and diluted (in dollars per share)
-0.74	-0.60	-0.58	-0.69	-0.69	-0.70	-0.52	-0.36	-0.38	-0.32	-0.31	-0.44	-0.41	-0.42
Weighted average common shares outstanding, basic and diluted (in shares)
28,799	28,291	28,221	28,204	28,203	28,194	26,589	25,652	25,290	17,332	17,332	17,332	17,332	17,332
Product sales, net
Revenue
11,812	13,288	11,729	7,728	0	0	0	-	-	-	-	-	-	-
Other revenue
Revenue
0	0	-	2,627	0	0	-	-	-	-	-	-	-	-